Gapping up
In reaction to earnings/guidance:

• BCRX +12.5%, HSIC +4.1%, JBTM +1.7%, ARES +1.2%

Other news:

• HHH +8.2% (receives $900 million investment from Pershing Square for nine million newly issued shares of Howard Hughes Holdings and transform HHH into a diversified holding company)
• TEVA +6.1% (Teva Pharma and Alvotech (ALVO) announce FDA approval of interchangeability for SELARSDI with Stelara)
• FFAI +3.4% (announces another binding pre-order agreement)
• NEM +2.8% (promotes Natascha Viljoen to President and COO)
• USAU +2.2% (files for $150 mln mixed securities shelf offering)
• ELAN +1.9% (sells royalty and milestone rights for Lotilaner in human health to Blackstone (BX); accelerates debt paydown)
• LQDA +0.8% (District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia)  

Gapping down
In reaction to earnings/guidance:

• AXSM -6.2%, OCUL -4.5%, IART -2.8%, FRPT -2.8%, CNA -2.6%, BRK.B -2.5% (also Warren Buffett at shareholder meeting asks board to have Greg Abel replace him as CEO at year end) TGTX -1.7%, IDCC -1.5%

Select Index ETFs showing early weakness:

• QQQ -0.9%, IWM -0.8%, SPY -0.7%, DIA -0.6%

Other news:

• PTCT -19.5% (reports PTC518 PIVOT-HD Study Achieves Primary Endpoint)
• IBRX -8.7% (requests an urgent meeting with FDA to address the change in the agency's unambiguous guidance on Jan 2025 to submit a sBLA for NMIBC BCG unresponsive papillary disease)
• LPTH -7.2% (files for 21,193,380 share common stock offering by selling shareholders)
• USCB -3.6% (files for $100 mln mixed securities shelf offering; files for 9,004,218 share common stock offering by selling shareholders)
• CIFR -3.5% (announces April 2025 Operational Update)
• NAVI -2.9% (files mixed securities shelf offering)
• TRC -2.6% (Leading Proxy Advisory Firm ISS Recommends Shareholders Vote "FOR" ONLY Tejon's 10 Director Nominees)
• RXRX -2.5% (reports preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden)
• NBIS -2.3% (files mixed securities shelf offering)
• OUST -2.3% (files for $200 mln mixed securities shelf offering)
• AORT -2% (Artivion Announces Presentation of New Clinical Data from NEXUS TRIOMPHE IDE Trial at the 105th American Association for Thoracic Surgery (AATS) Annual Meeting)
• NTRA -1.2% (announces the results of a study led by Stanford University School of Medicine for the evaluation of Signatera, Natera's personalized molecular residual disease test, in patients with soft tissue and bone sarcomas)